At Billionairesportfolio.com we actively manage a portfolio of the “best ideas” from the world’s best hedge funds, and our members get to follow along.
Following the highest conviction trades of the world’s best hedge funds works especially well in the biotech sector. It gives you direct access to the smartest investment minds with a niche concentration in science and medicine. They work for you, for free. This is critical, because there is no more complicated sector than biotech. You virtually need an MD or PhD from Harvard or Johns Hopkins to understand these companies.
With that said, the following four stocks are all owned by some of the best biotech hedge funds in the world. Moreover, they all have an average analyst price target that is at least 200% higher than its current share price.
1) AcelRX Pharmaceuticals (ACRX) has a current share price of $7. The consensus analyst price target is $15. That gives us a “street projected return” of 114%. Perceptive Advisors owns more than 15% of ACRX. Perspective is one of the top performing biotech hedge funds in the world, managing more than a billion dollars and returning an incredible 42% annualized since 1999. If you would have invested $10,000 in Perceptive in 1999, you would now have $1.3 million.
2) Ocera Therapeutics (OCRX) has a current share of $6.97. The consensus analyst price target is $17. That gives us a “street projected return of 143%. Ocera is owned by RA Capital Management, another top biotech focused hedge fund. RA Capital has returned 40% annualized since 2002, without one losing year, and is run by Peter Kolchinsky, a Harvard PhD in Virology.
3) Ariad Pharmaceuticals (ARIA) has a current share price of $6.50. The consensus analyst price target is $14. That gives us a “street projected return of 115%. Ariad is owned by one of the best emerging biotech hedge funds, Sarissa Capital Management. Sarissa is run by Alex Denner, a Yale PhD and the former head of healthcare investments for Carl Icahn. Sarissa owns almost 7% of Ariad.
4) Infinity Pharmaceuticals (INFI) has a current share price of $15. The consensus analyst price target is $39. That gives us a “street projected return of 160%. INFY is owned by one of the best and longest running biotech focused hedge funds, Orbimed Advisors. Orbimed runs over $10 billion dollars. The fund is run by the Princeton educated Samuel Isaly, and has returned 27% annualized since 1993. Orbimed owns almost 10% of Infinity Pharmaceuticals.
BillionairesPortfolio.com empowers self directed investors with an actively managed portfolio of the best ideas from the best hedge funds in the world. You can look over the shoulders of the smartest, most influential investors in the world. Click here to join.